Crystal form of compound, and pharmaceutical composition and use thereof

WO2024234619A1PCT designated stage expired Publication Date: 2024-11-21SHENZHEN KEYE HEALTH CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/135583
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2023-11-30
Publication Date
2024-11-21

Smart Images

  • Figure PCTCN2023135583-FTAPPB-I100001
    Figure PCTCN2023135583-FTAPPB-I100001
  • Figure PCTCN2023135583-FTAPPB-I100002
    Figure PCTCN2023135583-FTAPPB-I100002
  • Figure PCTCN2023135583-FTAPPB-I100003
    Figure PCTCN2023135583-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention relates to a crystal form of a compound, and a pharmaceutical composition and the use thereof, and specifically relates to different crystal forms of 1-(3-cyano-5-methylthiophen-2-yl)-N-(6-methoxy-1H-benzo[d]imidazol-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxamide, a pharmaceutical composition comprising the crystal form and the use.
Need to check novelty before this filing date? Find Prior Art

Description

Crystal form, pharmaceutical composition and use of a compound Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemistry and relates to different crystalline forms of 1-(3-cyano-5-methylthiophen-2-yl)-N-(6-methoxy-1H-benzo[d]imidazol-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxamide (hereinafter referred to as "the compound of formula (1)"), as well as pharmaceutical compositions containing the crystalline forms and their medical uses. Background Art

[0002] DHX33 belongs to the family of RNA helicase proteins containing the DEAD / H box. DEAD / H stands for the amino acid abbreviation Asp-Glu-Ala-Asp / His. This sequence, along with several other conserved amino acid sequences, is found in the protein sequences of members of the RNA helicase family and is highly involved in nucleic acid substrate binding and ATP hydrolysis. While these family members share these common sequences, each RNA helicase has unique specificity and biological functions. The human DHX33 protein has a molecular weight of 72 kDa and functions to unwind nucleic acids. It utilizes the bioenergy released by ATP hydrolysis to drive conformational changes in RNA-protein complexes, thereby participating in a variety of RNA metabolic activities, specifically, RNA transcription, splicing, editing, translation, and degradation. The functions of DHX33 are not limited to RNA modification. Research has shown that in addition to unwinding RNA duplexes, DHX33 also participates in DNA metabolism. Specifically, DHX33 can unwind the double-stranded structure of DNA and plays a vital role in gene expression.

[0003] Research has shown that DHX33 binds to the promoters of various cancer-related genes, affecting DNA methylation. This in turn regulates the expression of numerous cancer genes and signaling pathways associated with tumor development at the genomic level, playing a crucial role in numerous cellular activities, including cell growth, proliferation, migration, apoptosis, and metabolism. Furthermore, DHX33 has been shown to sense the intrusion of foreign double-stranded RNA molecules and play a crucial role in cellular innate immunity. As a crucial cell growth regulator, DHX33 is highly expressed in various cancers, including lung cancer, lymphoma, glioblastoma, breast cancer, colon cancer, and liver cancer. The development and progression of many cancers depend on elevated DHX33 protein expression. Genetic knockout of DHX33 significantly inhibits the development and progression of RAS oncogene-driven lung cancer. In vitro and in vivo experiments have confirmed that inhibition of DHX33 significantly suppresses the development and progression of various cancers, including breast cancer, colon cancer, glioma, and lymphoma. Since the protein function of DHX33 depends on its helicase activity, and the helicase activity-deficient mutant of DHX33 does not have the function of DHX33 protein, it cannot replace the function of the protein encoded by the wild-type DHX33 gene.

[0004] The applicant has discovered a variety of compounds that can inhibit the RNA helicase activity of DHX33 (for example, 1-(3-cyano-5-methylthiophen-2-yl)-N-(6-methoxy-1H-benzo[d]imidazol-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxamide) and verified that these compounds can significantly inhibit the growth and proliferation of cancer cells both in vitro and in vivo.

[0005] Summary of the Invention

[0006] The object of the present invention is to provide different crystalline forms of 1-(3-cyano-5-methylthiophen-2-yl)-N-(6-methoxy-1H-benzo[d]imidazol-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxamide (hereinafter referred to as "the compound of formula (1)"), a pharmaceutical composition containing the crystalline form, and uses.

[0007] The structural formula of the compound of formula (1) is as follows:

[0008] In a first aspect, the present invention provides an anhydrate crystalline form A of the compound of formula (1), whose X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at the following 2θ angles: 5.36±0.2°, 12.17±0.2° and 10.85±0.2°.

[0009] In some embodiments, the X-ray powder diffraction pattern of the anhydrate crystalline form A of the compound of formula (1) further has characteristic diffraction peaks at one or more of the following 2θ angles: 14.26±0.2°, 9.12±0.2° and 8.26±0.2°.

[0010] In some embodiments, the X-ray powder diffraction pattern of the anhydrate crystalline form A of the compound of formula (1) further has characteristic diffraction peaks at one or more of the following 2θ angles: 19.77±0.2°, 20.03±0.2° and 22.17±0.2°.

[0011] The present invention also provides a method for preparing the anhydrate crystalline form A of the compound of formula (1), comprising any one of the following methods:

[0012] (1) suspending the compound of formula (1) in a solvent and stirring at 5-35° C. for 1-3 days to obtain a crystalline wet sample of Form B; drying Form B at room temperature to convert it into anhydrous Form A; the solvent is selected from ethanol and a mixed solvent of ethyl acetate and isopropanol;

[0013] (2) suspending the compound of formula (1) in a solvent, stirring at 4-8° C. for 14-18 days, and separating the solid to obtain anhydrous crystalline form A; the solvent is selected from methanol, a mixed solvent of acetone and water, a mixed solvent of ethyl acetate and isopropanol, a mixed solvent of methyl tert-butyl ether and methyl ethyl ketone, a mixed solvent of 2-methyltetrahydrofuran and n-heptane, a mixed solvent of tetrahydrofuran and isopropyl acetate, and a mixed solvent of cyclopentyl methyl ether and tetrahydrofuran;

[0014] (3) suspending the compound of formula (1) in a solvent, stirring at room temperature for 14-18 days, and separating the solid to obtain anhydrous crystalline form A; the solvent is selected from ethanol, isopropyl acetate, a mixed solvent of dichloromethane and methanol, a mixed solvent of methyl ethyl ketone and methylcyclohexane, a mixed solvent of 1,4-dioxane and toluene, a mixed solvent of isopropyl alcohol and water, a mixed solvent of methyl isobutyl ketone and acetonitrile, and a mixed solvent of acetone and ethyl acetate;

[0015] (4) Anhydrous Form C is dried at room temperature and converted into anhydrous Form A.

[0016] In some embodiments, the compound of formula (1) is suspended in a solvent and stirred at 5-35° C. for about 1-3 days to obtain a crystalline wet sample of Form B. Form B is dried at room temperature for 1 day to transform into anhydrous Form A. The solvent is selected from ethanol and a mixed solvent of ethyl acetate and isopropanol (volume ratio of 1:1).

[0017] In some embodiments, the compound of formula (1) is dissolved in a solvent and filtered to obtain a clear solution. A vial containing the clear solution is sealed with a sealing film with a pinhole, and the solution is slowly evaporated at room temperature. The resulting solid is collected to obtain anhydrous crystalline Form A. The solvent is selected from a mixed solvent of acetone and acetonitrile (volume ratio of 3:1), a mixed solvent of ethyl acetate, tetrahydrofuran and water (volume ratio of 1:1), a mixed solvent of dichloromethane and cyclopentyl methyl ether (volume ratio of 1:1), and a mixed solvent of toluene and tetrahydrofuran (volume ratio of 2:1).

[0018] In some embodiments, the compound of formula (1) is suspended in a solvent, stirred at 4-8° C. for about 14-18 days, and then the solid is separated to obtain anhydrous crystalline Form A. The solvent is selected from a mixed solvent of methanol, acetone and water (volume ratio of 1:2), a mixed solvent of ethyl acetate and isopropanol (volume ratio of 1:1), a mixed solvent of methyl tert-butyl ether and methyl ethyl ketone (volume ratio of 1:1), a mixed solvent of 2-methyltetrahydrofuran and n-heptane (volume ratio of 1:1), a mixed solvent of tetrahydrofuran and isopropyl acetate (volume ratio of 1:4), and a mixed solvent of cyclopentyl methyl ether and tetrahydrofuran (volume ratio of 4:1).

[0019] In some embodiments, the compound of formula (1) is suspended in a solvent, stirred at room temperature for about 14-18 days, and then the solid is separated to obtain anhydrous crystalline Form A. The solvent is selected from ethanol, isopropyl acetate, a mixed solvent of dichloromethane and methanol (volume ratio of 1:4), a mixed solvent of methyl ethyl ketone and methylcyclohexane (volume ratio of 1:2), a mixed solvent of 1,4-dioxane and toluene (volume ratio of 1:3), a mixed solvent of isopropanol and water (volume ratio of 1:1), a mixed solvent of methyl isobutyl ketone and acetonitrile (volume ratio of 1:1), and a mixed solvent of acetone and ethyl acetate (volume ratio of 1:5).

[0020] In some embodiments, the compound of formula (1) is suspended in a solvent, stirred at 50° C. for about 7 days, then stirred at 5° C. for about 11 days, and the solid is separated to obtain anhydrous crystalline Form A. The solvent is selected from a mixed solvent of cyclopentyl methyl ether and ethanol (volume ratio of 1:1), a mixed solvent of tetrahydrofuran and water (volume ratio of 1:6), and a mixed solvent of 1,4-dioxane and n-hexane (volume ratio of 1:3).

[0021] In some embodiments, the compound of formula (1) is suspended in a solvent, then heated to 50°C, equilibrated for about two hours, filtered, and the filtrate slowly cooled to room temperature in a water bath. The solid is separated to obtain anhydrous crystalline Form A. The solvent is selected from methanol.

[0022] In some embodiments, the compound of formula (1) is dissolved in a positive solvent and filtered to obtain a clear solution. The vial containing the clear solution is then placed in another vial containing a volatile anti-solvent, the vial is sealed with a cap, and kept at room temperature for about 1-3 days. The solid is separated to obtain anhydrous crystalline Form A. The positive solvent is selected from a mixed solvent of 1,4-dioxane and toluene (volume ratio of 4: 1), a mixed solvent of methyl ethyl ketone and acetonitrile (volume ratio of 4: 1), and a mixed solvent of chloroform and methyl isobutyl ketone (volume ratio of 2: 1). The anti-solvent is selected from n-pentane and n-heptane.

[0023] In some embodiments, the compound of formula (1) is suspended in a solvent and stirred under temperature cycling conditions. The solid is separated to obtain anhydrous crystalline form A. The solvent is selected from a mixed solvent of isopropyl acetate and cyclopentyl methyl ether (volume ratio of 1: 1), a mixed solvent of methanol and methyl ethyl ketone (volume ratio of 4: 1), a mixed solvent of ethyl acetate and chloroform (volume ratio of 5: 1), a mixed solvent of tetrahydrofuran and n-heptane (volume ratio of 1: 5), a mixed solvent of 1,4-dioxane and methyl tert-butyl ether (volume ratio of 1: 3), and a mixed solvent of methyl isobutyl ketone and methylcyclohexane (volume ratio of 1: 1). The temperature cycling conditions are equilibration at 50°C for about 120 minutes, then cooling to 5°C at a rate of 0.1°C / min, equilibration at 5°C for about 120 minutes, and performing this cycle twice.

[0024] In a second aspect, the present invention provides an anhydrate crystalline form C of the compound of formula (1), whose X-ray powder diffraction (XRPD) pattern has characteristic diffraction peaks at the following 2θ angles: 5.73±0.2°, 8.16±0.2° and 12.94±0.2°.

[0025] In some embodiments, the X-ray powder diffraction pattern of the anhydrate crystalline form C of the compound of formula (1) further has characteristic diffraction peaks at one or more of the following 2θ angles: 11.55±0.2°, 15.10±0.2° and 18.37±0.2°.

[0026] In some embodiments, the X-ray powder diffraction pattern of the anhydrate crystalline form C of the compound of formula (1) further has characteristic diffraction peaks at one or more of the following 2θ angles: 13.29±0.2°, 8.73±0.2° and 23.61±0.2°.

[0027] The present invention also provides a method for preparing the anhydrate crystal form C of the compound of formula (1), comprising any one of the following methods:

[0028] (1) suspending the compound of formula (1) in a solvent and stirring at 5-35° C. for 1-3 days to obtain a crystalline wet sample of Form B; drying Form B at 50-80° C. to convert it into anhydrous Form C; the solvent is selected from ethanol and a mixed solvent of ethyl acetate and isopropanol;

[0029] (2) suspending the compound of formula (1) in a solvent, stirring at 4-8° C. for 3 days, and separating the solid to obtain anhydrous crystalline form C; the solvent is selected from a mixed solvent of ethyl acetate and isopropanol;

[0030] (3) The compound of formula (1) is suspended in a solvent, stirred at room temperature for 14-18 days, and then the solid is separated to obtain anhydrous crystal form C; the solvent is selected from a mixed solvent of acetonitrile and water.

[0031] In some embodiments, the compound of formula (1) is suspended in a solvent and stirred at 5-35° C. for about 1-3 days to obtain a crystalline wet sample of Form B. Form B is dried at 50-80° C. for 2-12 hours to transform into anhydrous Form C. The solvent is selected from ethanol and a mixed solvent of ethyl acetate and isopropanol (volume ratio of 1:1).

[0032] In some embodiments, the compound of formula (1) is suspended in a solvent, stirred at 4-8° C. for about 3 days, and then the solid is separated to obtain anhydrous crystalline Form C. The solvent is selected from a mixed solvent of ethyl acetate and isopropanol (volume ratio of 1:1).

[0033] In some embodiments, the compound of formula (1) is suspended in a solvent, stirred at 4-8° C. for about 18 days, and then the solid is separated to obtain anhydrous crystalline Form C. The solvent is selected from a mixed solvent of dichloromethane and acetonitrile (volume ratio of 1:3).

[0034] In some embodiments, the compound of formula (1) is suspended in a solvent, then heated to 50°C, equilibrated for about two hours, filtered, and the filtrate slowly cooled to room temperature in a water bath. The solid is isolated to obtain anhydrous Form C. The solvent is selected from a mixed solvent of acetonitrile and water (volume ratio of 3:1).

[0035] In some embodiments, the compound of formula (1) is suspended in a solvent and stirred under temperature cycling conditions. The solid is separated to obtain anhydrous Form C. The solvent is selected from acetonitrile. The temperature cycling conditions are equilibrated at 50°C for approximately 120 minutes, then cooled to 5°C at a rate of 0.1°C / min, and equilibrated at 5°C for approximately 120 minutes, and this cycle is repeated twice.

[0036] In some embodiments, the compound of formula (1) is suspended in a solvent, stirred at room temperature for about 14-18 days, and then the solid is separated to obtain anhydrous crystalline Form C. The solvent is selected from a mixed solvent of acetonitrile and water (volume ratio is 1:1).

[0037] In some embodiments, the compound of formula (1) is suspended in a solvent, stirred at 4-8° C. for about 18 days, and the solid is separated to obtain Form D, which is then dried at room temperature for 1 day to convert into anhydrous Form C. The solvent is selected from a mixed solvent of toluene and ethanol (volume ratio of 1:1).

[0038] In a third aspect, the present invention provides a pharmaceutical composition comprising at least one of the above-mentioned crystal forms and one or more pharmaceutically acceptable carriers.

[0039] In a fourth aspect, the present invention provides use of the above-mentioned crystal form or the above-mentioned pharmaceutical composition in the preparation of a medicament for preventing and / or treating a disease or condition mediated by DHX33.

[0040] In a fifth aspect, the present invention provides a method for preventing and / or treating a disease or condition mediated by DHX33, comprising the following steps: administering a preventive and / or therapeutically effective amount of the above-mentioned crystalline form or the above-mentioned pharmaceutical composition to an individual in need thereof; preferably, the disease is selected from DHX33-mediated cancer, viral infection and inflammation.

[0041] The present invention is not to be limited to the particular embodiments described herein; it is also to be understood that the terminology used herein is for the purpose of describing and not limiting particular embodiments.

[0042] Definition of terms

[0043] Unless otherwise stated, the technology and scientific terms used herein have the same meaning as those skilled in the art to which the present invention pertains. If there is a contradiction, the definition provided herein shall prevail. When a certain amount, concentration or other value or parameter is expressed in the form of a range, a preferred range or a preferred upper numerical limit and a preferred lower numerical limit, it should be understood that it is equivalent to specifically disclosing any scope by combining any pair of upper range limits or preferred values ​​with any lower range limit or preferred values, without considering whether the scope is specifically disclosed. Unless otherwise stated, the numerical ranges listed herein are intended to include all integers and fractions (decimals) within the endpoints and range of the range.

[0044] The term "about" when used in conjunction with a numerical variable generally means that the value of that variable and all values ​​of that variable are within experimental error (e.g., within a 95% confidence interval for the mean) or within ±10% of the stated value, or wider.

[0045] The expression "comprising" or its synonyms "including," "containing," and "having" are open-ended and do not exclude additional unrecited elements, steps, or ingredients. The expression "consisting of excludes any elements, steps, or ingredients not specified. The expression "consisting essentially of" means that the scope is limited to the specified elements, steps, or ingredients, plus any optional elements, steps, or ingredients that do not materially affect the basic and novel characteristics of the claimed subject matter. It should be understood that the expression "comprising" encompasses the expressions "consisting essentially of" and "consisting of."

[0046] The term "X-ray powder diffraction pattern (XRPD pattern)" refers to an experimentally observed diffraction pattern or a parameter, data or value derived therefrom. An XRPD pattern is typically characterized by peak positions (abscissa) and / or peak intensities (ordinate).

[0047] The term "diffraction angle" or "2θ" refers to the peak position expressed in degrees (°) based on the setup in the X-ray diffraction experiment and is generally the unit of the abscissa in the diffraction pattern. If the incident beam forms an angle θ with a certain lattice plane and the reflection is diffracted, the experimental setup requires that the reflected beam be recorded in 2θ angles. It should be understood that references herein to a specific 2θ value for a specific crystalline form are intended to represent the 2θ value (expressed in degrees) measured using the X-ray diffraction experimental conditions described herein.

[0048] It should be noted that the positions or relative intensities of peaks in powder X-ray diffraction spectra may vary due to factors such as the measuring instrument, measurement method, and conditions. For any particular crystal form, the peak positions may have errors, and the measurement error of the 2θ value can be ±0.2°. Therefore, this error should be taken into account when determining each crystal form, and determinations within this error are within the scope of this application.

[0049] For the same crystal form, the position of the DSC endothermic peak may vary due to factors such as the measuring instrument, measurement method / conditions, etc. For any particular crystal form, the position of the endothermic peak may have an error of ±5°C or even ±3°C. Therefore, this error should be taken into account when determining the crystal form, and any error within this error is within the scope of this application.

[0050] For the same crystal form, the location of the weight loss temperature on TGA may vary due to factors such as the measuring instrument, measurement method / conditions, etc. For any particular crystal form, the location of the weight loss temperature may have an error of ±5°C or even ±3°C. Therefore, this error should be taken into account when determining the weight loss temperature of each crystal form, and any error within this error is within the scope of this application.

[0051] It should be understood that different types of equipment or using different test conditions may give slightly different XRPD patterns and characteristic peaks or different DSC patterns and characteristic peaks. The specific numerical values ​​provided should not be regarded as absolute values.

[0052] The term "room temperature" refers to 20°C ± 5°C.

[0053] The term "prevent" refers to prophylactic administration to reduce the likelihood of or delay the onset of a disease or symptom.

[0054] The term "treatment" is intended to alleviate or eliminate the disease state or condition being treated. It should also be understood that treatment of the disease state or condition includes not only complete treatment, but also less than complete treatment while achieving some biologically or medically relevant results.

[0055] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or crystalline forms that are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment. "Pharmaceutically acceptable carrier" refers to an inert substance that is administered together with the active ingredient and facilitates the administration of the active ingredient, including but not limited to any glidant, sweetener, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersant, disintegrant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier approved by the State Food and Drug Administration for use in humans or animals (e.g., livestock).

[0056] Above-mentioned pharmaceutical composition can act systemically and / or act topically.For this purpose, they can be administered by suitable approach, for example by parenteral, local, intravenous, oral, subcutaneous, intraarterial, intradermal, percutaneous, rectal, intracranial, intraperitoneal, intranasal, intramuscular approach or as inhalant administration.

[0057] The above-mentioned route of administration can be achieved through suitable dosage forms. The dosage forms that can be used in the present invention include, but are not limited to, tablets, capsules, lozenges, hard candies, powders, sprays, creams, ointments, suppositories, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, etc.

[0058] When administered orally, the pharmaceutical composition can be prepared into any orally acceptable preparation form, including but not limited to tablets, capsules, aqueous solutions, aqueous suspensions, and the like.

[0059] The term "disease or condition mediated by DHX33" refers to a disease whose pathogenesis at least partially involves factors related to DHX33, such as cancer, viral infection, and inflammation.

[0060] The term "effective amount" refers to a dose that can induce a biological or medical response in cells, tissues, organs or organisms (eg, individuals) and is sufficient to achieve the desired preventive and / or therapeutic effect.

[0061] The therapeutically effective amount of the crystalline form described herein is from about 0.0001 to 20 mg / Kg body weight / day, for example, from 0.001 to 10 mg / Kg body weight / day.

[0062] The dosage frequency of the crystalline forms described herein is determined by the needs of the individual patient, for example, once or twice a day, or more times a day. Administration can be intermittent, for example, wherein the patient receives a daily dose of the crystalline form over a period of several days, followed by a period of several or more days in which the patient does not receive a daily dose of the crystalline form. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] Figure 1: X-ray powder diffraction (XRPD) pattern of Form E of the compound of formula (1).

[0064] Figure 2: Thermogravimetric analysis (TGA) of Form E.

[0065] Figure 3: Differential scanning calorimetry (DSC) diagram of Form E.

[0066] Figure 4: Crystalline Form E 1 H NMR spectrum.

[0067] Figure 5: XRPD comparison charts of anhydrate crystalline form A, crystalline form B, anhydrate crystalline form C and crystalline form D of the compound of formula (1).

[0068] Figure 6: XRPD comparison of wet and dry samples in the preparation method of anhydrous form A.

[0069] Figure 7: X-ray powder diffraction (XRPD) pattern of anhydrous Form A.

[0070] Figure 8: Thermogravimetric analysis (TGA) of anhydrous Form A.

[0071] Figure 9: Differential scanning calorimetry (DSC) diagram of anhydrous form A.

[0072] Figure 10: Anhydrate Form A 1 H NMR spectrum.

[0073] Figure 11: XRPD comparison of anhydrate form A before and after heating.

[0074] Figure 12: Thermogravimetric analysis (TGA) of anhydrate Form A after heating.

[0075] Figure 13: VT-XRPD pattern of anhydrate form A.

[0076] Figure 14: X-ray powder diffraction (XRPD) pattern of anhydrate Form C.

[0077] Figure 15: XRPD comparison of wet and dry samples in one preparation method of anhydrous Form C.

[0078] Figure 16: Thermogravimetric analysis (TGA) of anhydrate form C.

[0079] Figure 17: Differential scanning calorimetry (DSC) graph of anhydrous Form C.

[0080] Figure 18: Anhydrate Form C 1 H NMR spectrum.

[0081] Figure 19: XRPD comparison of wet and dry samples in another preparation method of anhydrous Form C.

[0082] Figure 20: X-ray powder diffraction (XRPD) pattern of Form B.

[0083] Figure 21: XRPD comparison of Form B before and after standing at room temperature.

[0084] Figure 22: X-ray powder diffraction (XRPD) pattern of Form D.

[0085] Figure 23: XRPD comparison of Form D before and after standing at room temperature.

[0086] Figure 24: XRPD comparison of suspension competition between anhydrous form A and anhydrous form C.

[0087] Figure 25: XRPD comparison of anhydrate Form A before and after solid-state stability testing.

[0088] Figure 26: XRPD comparison of anhydrate Form C before and after solid-state stability testing.

[0089] Figure 27: XRPD comparison of anhydrous Form A before and after high temperature stability test.

[0090] Figure 28: XRPD comparison of anhydrate Form C before and after high temperature stability test.

[0091] Figure 29: DVS test diagram of anhydrous form A.

[0092] Figure 30: XRPD comparison of anhydrate form A before and after DVS testing.

[0093] Figure 31: DVS test diagram of anhydrate form C.

[0094] Figure 32: XRPD comparison of anhydrate form C before and after DVS testing. DETAILED DESCRIPTION

[0095] The intermediate compounds of the present application can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent replacement methods well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present application.

[0096] The chemical reactions described in the specific embodiments of the present application are carried out in a suitable solvent that is compatible with the chemical transformations described herein and the reagents and materials required. To obtain the compounds described herein, it may sometimes be necessary for those skilled in the art to modify or select synthetic steps or reaction schemes based on existing embodiments.

[0097] The present application will be described in detail below through examples, which are not intended to limit the present application in any way.

[0098] X-ray powder diffraction (XRPD)

[0099] XRPD test parameters

[0100] Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC)

[0101] TGA and DSC test parameters

[0102] H NMR spectrum ( 1 HNMR)

[0103] 1 H NMR test parameters

[0104] High-performance liquid chromatography (HPLC)

[0105] HPLC test parameters

[0106] Dynamic Water Sorption Analysis (DVS)

[0107] DVS test parameters

[0108] Solvent abbreviations and Chinese correspondence table

[0109] Example 1: Preparation of the compound of formula (1) (1-(3-cyano-5-methylthiophen-2-yl)-N-(6-methoxy-1H-benzo[d]imidazol-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxamide)

[0110] (1) Preparation method of compound 3 (ethyl 2-acetyl-4-pentanoate)

[0111] Compound 1 (ethyl acetoacetate) (5 g, 38.42 mmol, 1.0 eq) was dissolved in triethylamine (75 mL), and compound 2 (chloroacetone) (3.5 g, 38.42 mmol, 1.0 eq) was added. The reactants were reacted at 110° C. for 2 hours under nitrogen protection. After concentration, the residue was dissolved in water (100 mL) and then extracted twice with dichloromethane (50 mL each). The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and then concentrated. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate = 100 / 1 to 50 / 1 to 20 / 1) to obtain compound 3 (ethyl 2-acetyl-4-pentanoate) (1.3 g, yield: 18.3%) as a colorless oil. MS (ESI) m / z: 187 [M+H + ]. TLC: PE / EA (2 / 1); R f (Compound 1) = 0.6; R f (Compound 3) = 0.4.

[0112] (2) Preparation method of compound 5 (1-(3-cyano-5-methylthiophene-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester)

[0113] Compound 3 (ethyl 2-acetyl-4-pentanoate) (1 g, 7.23 mmol, 1.0 eq) was dissolved in toluene (20 mL), and compound 4 (2-amino-3-cyano-5-methylthiophene) (1.6 g, 8.68 mmol, 1.2 eq) and p-toluenesulfonic acid (249 mg, 1.45 mmol, 0.2 eq) were added. The reaction was stirred at 110°C for 16 hours. The solid was filtered and concentrated. The residue was purified by flash column chromatography (petroleum ether / ethyl acetate = 50 / 1 to 30 / 1) to obtain yellow oily compound 5 (ethyl 1-(3-cyano-5-methylthiophene-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxylate) (860 mg, yield: 41%). MS (ESI) m / z: 289 [M+H + ]. TLC: petroleum ether / ethyl acetate (10 / 1); R f (Compound 3) = 0.2; R f(Compound 5) = 0.4.

[0114] (3) Preparation method of compound of formula (1)

[0115] To compound 5 (ethyl 1-(3-cyano-5-methylthiophen-2-yl)-2,5-dimethyl-1H-pyrrole-3-carboxylate) (50 mg, 0.306 mmol, 1.0 eq) and compound 7 (5-methoxy-1H-benzimidazol-2-amine) (88 mg, 0.306 mmol, 1.0 eq) dissolved in 1 mL of toluene was added trimethylaluminum (0.15 mL, 0.306 mmol, 1.0 eq, 2 M in toluene). The reaction was stirred at 100°C for 16 hours. The mixture was cooled to room temperature, quenched with methanol (10 mL), and then adjusted to pH 3 with 3 M hydrochloric acid. The mixture was diluted with water (30 mL) and extracted three times with 20 mL of ethyl acetate each time. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by preparative high pressure liquid phase Prep-HPLC (acetonitrile / water (containing 0.1% formic acid)) to obtain the compound of formula (1) (5 mg, yield: 4%), which exists in the form of weakly crystalline form E. MS (ESI) m / z: 406 [M+H + ]. 1 H NMR (400MHz, DMSO-d6): δ12.04(s,1H),11.20(s,1H),7.32(s,1H),7.29(s,1H),6.98(s,1H ), 6.89 (s, 1H), 6.69 (d, J = 7.2Hz, 1H), 3.73 (s, 3H), 2.47 (s, 3H), 2.38 (s, 3H), 2.04 (s, 3H). 1 The H NMR data are shown in Figure 4.

[0116] Form E has an XRPD pattern substantially as shown in Figure 1 .

[0117] As shown in FIG2 , the thermogravimetric analysis (TGA) curve of Form E shows a weight loss of approximately 2.56% when the temperature is raised to approximately 140° C.

[0118] As shown in FIG3 , the differential scanning calorimetry (DSC) curve of Form E has an endothermic peak at approximately 165.55° C.

[0119] Example 2: Crystalline form of the compound of formula (1) and its preparation method

[0120] Preparation method of anhydrous crystal form A of the compound of formula (1)

[0121] Approximately 199.79 mg of the compound of formula (1) was weighed and suspended in 5.0 mL of EtOH. The suspension was magnetically stirred at room temperature for 1 day, resulting in a crystalline wet sample of Form B. Form B was air-dried at room temperature for 1 day, transforming into anhydrous Form A. XRPD comparisons of the wet and dry samples from this preparation method are shown in Figure 6.

[0122] Anhydrate Form A has an XRPD pattern substantially as shown in FIG7 .

[0123] The XRPD pattern of the anhydrate crystalline form A has characteristic diffraction peaks at the following 2θ angles, as shown in Table 1:

[0124] Table 1

[0125] As shown in FIG8 , the thermogravimetric analysis (TGA) curve of the anhydrate crystalline form A shows a weight loss of approximately 2.70% when the temperature is raised to approximately 130° C.

[0126] As shown in FIG9 , the differential scanning calorimetry (DSC) curve of the anhydrate crystalline form A has an endothermic peak at approximately 167.75° C.

[0127] As shown in Figure 10, the anhydrate crystal form A 1 The H NMR spectrum showed no obvious residual solvent.

[0128] As shown in FIG11 , in the heating experiment, the anhydrate crystalline form A was heated to 120° C. for 5 minutes and then cooled to room temperature without changing the crystalline form. As shown in FIG12 , the TGA analysis of the heated sample showed a weight loss of 2.49%.

[0129] As shown in FIG13 , in VT-XRPD (variable temperature XRPD), the anhydrate crystalline form A was heated to 120° C., and in-situ XRPD detection showed that the crystalline form did not change; and then the temperature was lowered to room temperature, and the crystalline form did not change.

[0130] Preparation method of crystal form B of compound of formula (1)

[0131] Approximately 199.81 mg of the compound of formula (1) was weighed and suspended in 5.0 mL of a mixed solvent of methyl ethyl ketone and toluene (volume ratio 1:2). The suspension was magnetically stirred at 50°C for 3 days. The resulting crystalline wet sample was Form B. Form B is a metastable form. Form B transformed into anhydrous Form A after drying at room temperature for 1 day. XRPD comparison patterns of the wet and dry samples from this preparation method are shown in Figure 21.

[0132] Form B has an XRPD pattern substantially as shown in Figure 20.

[0133] The XRPD pattern of Form B has characteristic diffraction peaks at the following 2θ angles, as shown in Table 2:

[0134] Table 2

[0135] Preparation method of anhydrous crystal form C of compound of formula (1)

[0136] Method 1: Approximately 200.07 mg of the compound of formula (1) was suspended in 5.0 mL of a 1:1 volume ratio of ethyl acetate and isopropanol. The suspension was magnetically stirred at room temperature for 1 day. The resulting wet crystalline sample was Form B. Form B was dried at 50°C for 4 hours to convert to its anhydrate, Form C. A comparison of the XRPD patterns of the wet and dry samples prepared using this method is shown in Figure 15.

[0137] Method 2: Approximately 199.63 mg of the compound of formula (1) was weighed and suspended in 5.0 mL of a mixed solvent of ethyl acetate and isopropanol (1:1 by volume). The suspension was magnetically stirred at 4-8°C for 3 days. The resulting wet crystalline sample was anhydrous Form C. This anhydrous Form C was air-dried at room temperature for 1 day, converting to anhydrous Form A. XRPD comparisons of the wet and dry samples from this preparation method are shown in Figure 19.

[0138] Anhydrate Form C has an XRPD pattern substantially as shown in FIG14 .

[0139] The XRPD pattern of the anhydrate crystalline form C has characteristic diffraction peaks at the following 2θ angles, as shown in Table 3:

[0140] Table 3

[0141] As shown in FIG16 , the thermogravimetric analysis (TGA) curve of the anhydrate crystalline form C shows a weight loss of approximately 1.49% when the temperature is raised to approximately 130° C.

[0142] As shown in FIG17 , the differential scanning calorimetry (DSC) curve of the anhydrate crystalline form C has an endothermic peak at approximately 162.13° C.

[0143] As shown in Figure 18, the anhydrate crystal form C 1 The H NMR spectrum showed no obvious residual solvent.

[0144] Preparation method of crystal form D of compound of formula (1)

[0145] Approximately 19.82 mg of the compound of formula (1) was weighed and suspended in 5.0 mL of a mixed solvent of toluene and ethanol (1:1 by volume). The suspension was magnetically stirred at 4-8°C for 18 days, yielding a crystalline wet sample of Form D. Form D is a metastable form. Form D was air-dried at room temperature for one day, transforming into its anhydrate, Form C. A comparison of the XRPD patterns of the wet and dry samples from this preparation method is shown in Figure 23.

[0146] Form D has an XRPD pattern substantially as shown in Figure 22.

[0147] The XRPD pattern of Form D has characteristic diffraction peaks at the following 2θ angles, as shown in Table 4:

[0148] Table 4

[0149] The XRPD comparison patterns of the anhydrate crystalline form A, crystalline form B, anhydrate crystalline form C and crystalline form D of the compound of formula (1) are shown in FIG5 .

[0150] Example 3: Suspension competition test

[0151] In order to confirm the interconversion relationship between anhydrate crystalline form A and anhydrate crystalline form C, suspension competition experiments were conducted in EtOH (room temperature and 50°C) and IPAc (room temperature and 50°C), respectively. First, a suspension of the compound of formula (1) equilibrated at the corresponding temperature and solvent for 2 hours was filtered to obtain a saturated solution of the compound of formula (1) at different temperatures and solvents, and then a solid mixture of anhydrate crystalline form A and anhydrate crystalline form C was added.

[0152] As shown in Table 5 and Figure 24, the mixture of anhydrate crystalline Form A and anhydrate crystalline Form C was converted into anhydrate crystalline Form A and crystalline Form B, indicating that crystalline Form B is relatively more stable in the case of a wet sample within the range of room temperature to 50°C. Anhydrate crystalline Form A is a thermodynamically more stable anhydrate within the range of room temperature to 50°C.

[0153] Table 5 / : Not detected.

[0154] Example 4: Solid-state stability

[0155] Anhydrous Form A and anhydrous Form C were placed under long-term (25° C. / 60% RH) and accelerated (40° C. / 75% RH) conditions for 10 days, respectively, and then tested for HPLC purity and crystal form change.

[0156] As shown in Table 6 and Figures 25 and 26, no crystalline form change or significant decrease in HPLC purity was observed for the anhydrate crystalline form A and the anhydrate crystalline form C, indicating that the anhydrate crystalline form A and the anhydrate crystalline form C have good physical and chemical stability under the experimental conditions.

[0157] Table 6

[0158] Example 5: High temperature stability

[0159] After the anhydrate crystal form A and the anhydrate crystal form C were placed at 60° C. for 10 days, the HPLC purity and crystal form change were tested.

[0160] As shown in Table 7 and Figures 27 and 28, no crystalline form change or significant decrease in HPLC purity was observed for the anhydrate crystalline form A and the anhydrate crystalline form C, indicating that the anhydrate crystalline form A and the anhydrate crystalline form C have good physical and chemical stability under the experimental conditions.

[0161] Table 7

[0162] Example 6: Hygroscopicity Evaluation

[0163] To assess the stability risk of the samples with humidity changes at 25°C, DVS tests were performed on anhydrous Form A and anhydrous Form C, and the solid samples after the tests were collected for XRPD testing.

[0164] The results are shown in Table 8. At 80% RH, the anhydrated Form A absorbed 3.24% water, indicating slight hygroscopicity. The anhydrated Form C gained 3.71% weight upon water absorption, indicating slight hygroscopicity. DVS and XRPD test results are shown in Figures 29-32. No changes in the crystalline form of either Form A or Form C were observed before and after DVS testing.

[0165] Table 8 *: Hygroscopicity is based on the weight gain of the sample when the humidity rises to 80% RH at 25°C. Chinese Pharmacopoeia 2020: 2%-15% is considered hygroscopic.

[0166] Example 7: Polymorph screening experiment

[0167] Slow evaporation

[0168] Weigh approximately 20 mg of the compound of formula (1) and dissolve it in 1.0-3.0 mL of solvent. If it is not completely dissolved, filter the suspension using polytetrafluoroethylene, and the filtrate will be used in the subsequent steps. Seal the vial containing the clear solution with a sealing film with a pinhole and place it at room temperature to slowly evaporate. Collect the resulting solid and perform XRPD analysis. The test results are shown in Table 9, and anhydrous Form A was obtained.

[0169] Table 9

[0170] Low temperature 4-8℃ slurry conversion

[0171] Approximately 20 mg of the compound of formula (1) was weighed and suspended in 0.5 mL of solvent. The suspension was magnetically stirred at 4-8°C for approximately 18 days, and then the solid was isolated for XRPD analysis. The test results are shown in Table 10, and anhydrous crystalline Forms A / C were obtained.

[0172] Table 10

[0173] Room temperature slurry conversion

[0174] Approximately 20 mg of the compound of formula (1) was weighed and suspended in 0.5 mL of solvent. The suspension was magnetically stirred at room temperature for approximately 14-18 days, and then the solid was isolated for XRPD analysis. The test results are shown in Table 11, indicating that anhydrate crystalline Form A / C or Form B was obtained.

[0175] Table 11

[0176] 50℃ slurry conversion

[0177] Approximately 20 mg of the compound of formula (1) was weighed and suspended in 0.5 mL of solvent. The suspension was magnetically stirred at 50°C for approximately 7 days, then stirred at 5°C for approximately 11 days. The solid was then isolated and analyzed by XRPD. The test results are shown in Table 12, indicating that anhydrate crystalline Form A and Form B were obtained.

[0178] Table 12

[0179] Cooling crystallization

[0180] Approximately 20 mg of the compound of formula (1) was weighed and suspended in 1.0 mL of solvent. The suspension was then heated to 50°C, equilibrated for approximately two hours, and filtered through a polytetrafluoroethylene filter. The filtrate was slowly cooled to room temperature in a water bath. The isolated solid was subjected to XRPD analysis. The test results are shown in Table 13, yielding anhydrous Forms A / C.

[0181] Table 13

[0182] Gas-liquid diffusion

[0183] Approximately 20 mg of the compound of formula (1) was weighed and dissolved in 0.2-2.0 mL of a positive solvent and filtered to obtain a clear solution. The vial containing the clear solution was then placed into a 20 mL vial containing 3 mL of a volatile antisolvent. The 20 mL vial was sealed with a cap and maintained at room temperature to allow sufficient time for the organic vapor to interact with the solution. The solid was isolated and subjected to XRPD analysis. The test results are shown in Table 14, and anhydrous Form A was obtained.

[0184] Table 14

[0185] Gas-solid diffusion

[0186] Approximately 20 mg of the compound of formula (1) was weighed into a 3 mL vial and placed into a 20 mL vial containing 3 mL of a volatile solvent. The 20 mL vial was sealed with a lid and maintained at room temperature for 18 days to allow the solvent vapor to interact with the sample. The solid was collected and subjected to XRPD analysis. The test results are shown in Table 15, and anhydrous crystalline Form A and crystalline Form B were obtained.

[0187] Table 15

[0188] Water vapor stress

[0189] Approximately 20 mg of the compound of formula (1) was weighed into a 3 mL vial and placed under conditions of RT-75% relative humidity, RT-85% relative humidity, and RT-97% relative humidity for 18 days. The solid was collected and subjected to XRPD analysis. The test results are shown in Table 16. Only the anhydrate crystalline form A was obtained.

[0190] Table 16

[0191] polymer-induced

[0192] Weigh about 20 mg of the compound of formula (1) and dissolve it in 0.8-3.0 mL of solvent. If it is not completely dissolved, filter the suspension through polytetrafluoroethylene and use the filtrate in the subsequent steps. Add about 1 to 2 mg of polymer to each vial. Seal the vial containing the solution with a sealing film, poke a small hole, and evaporate slowly at room temperature. Collect the resulting solid and perform XRPD analysis. The test results are shown in Table 17, and anhydrous form A, form B, and anhydrous form A + form B were obtained.

[0193] Table 17

[0194] grinding

[0195] Grind approximately 20 mg of the compound of formula (1) in a mortar (or grind using a solvent). Isolate the solid and perform XRPD analysis. The test results are shown in Table 18, yielding anhydrous Form A.

[0196] Table 18

[0197] Cyclic heating and cooling

[0198] Approximately 20 mg of the compound of formula (1) was weighed and suspended in 0.5 mL of solvent. The suspension was magnetically stirred under the following temperature cycle conditions. The solid was isolated for XRPD analysis. The test results are shown in Table 19, and anhydrous Form A, Form B, and anhydrous Form C were obtained.

[0199] Table 19

[0200] Rotary evaporation

[0201] Approximately 50 mg of the compound of formula (1) was weighed and dissolved in 0.5-1.4 mL of solvent. The solution was filtered to obtain a clear solution. The solution was rotary evaporated at 50°C, and the solid was isolated for XRPD analysis. The test results are shown in Table 20, and anhydrous Form A was obtained.

[0202] Table 20 *: 3.0 g of the compound of formula (1).

Claims

1. An anhydrate crystalline form A of a compound of formula (1), in, The X-ray powder diffraction pattern of the anhydrate crystalline form A has characteristic diffraction peaks at the following 2θ angles: 5.36±0.2°, 12.17±0.2° and 10.85±0.2°; Preferably, the X-ray powder diffraction pattern of the anhydrate crystalline form A further has characteristic diffraction peaks at one or more of the following 2θ angles: 14.26±0.2°, 9.12±0.2° and 8.26±0.2°; Preferably, the X-ray powder diffraction pattern of the anhydrate crystalline form A further has characteristic diffraction peaks at one or more of the following 2θ angles: 19.77±0.2°, 20.03±0.2° and 22.17±0.2°; Preferably, the anhydrate crystalline form A has an X-ray powder diffraction pattern substantially as shown in FIG7 .

2. An anhydrate crystal form C of the compound of formula (1), in, The X-ray powder diffraction pattern of the anhydrous crystalline form C has characteristic diffraction peaks at the following 2θ angles: 5.73±0.2°, 8.16±0.2° and 12.94±0.2°; Preferably, the X-ray powder diffraction pattern of the anhydrate crystalline form C further has characteristic diffraction peaks at one or more of the following 2θ angles: 11.55±0.2°, 15.10±0.2° and 18.37±0.2°; Preferably, the X-ray powder diffraction pattern of the anhydrate crystalline form C further has characteristic diffraction peaks at one or more of the following 2θ angles: 13.29±0.2°, 8.73±0.2° and 23.61±0.2°; Preferably, the anhydrate crystalline Form C has an XRPD pattern substantially as shown in FIG14 .

3. A pharmaceutical composition comprising the crystal form according to claim 1 or 2, and one or more pharmaceutically acceptable carriers.

4. Use of the crystalline form according to claim 1 or 2 or the pharmaceutical composition according to claim 3 in the preparation of a medicament for preventing and / or treating a disease or condition mediated by DHX33; preferably, the disease is selected from DHX33-mediated cancer, viral infection and inflammation.

5. The method for preparing the anhydrate crystalline form A according to claim 1, comprising any one of the following methods: (1) suspending the compound of formula (1) in a solvent and stirring at 5-35° C. for 1-3 days to obtain a crystalline wet sample of Form B; drying Form B at room temperature to convert it into anhydrous Form A; the solvent is selected from ethanol and a mixed solvent of ethyl acetate and isopropanol; (2) suspending the compound of formula (1) in a solvent, stirring at 4-8° C. for 14-18 days, and separating the solid to obtain anhydrous crystalline form A; the solvent is selected from methanol, a mixed solvent of acetone and water, a mixed solvent of ethyl acetate and isopropanol, a mixed solvent of methyl tert-butyl ether and methyl ethyl ketone, a mixed solvent of 2-methyltetrahydrofuran and n-heptane, a mixed solvent of tetrahydrofuran and isopropyl acetate, and a mixed solvent of cyclopentyl methyl ether and tetrahydrofuran; (3) suspending the compound of formula (1) in a solvent, stirring at room temperature for 14-18 days, and separating the solid to obtain anhydrous crystalline form A; the solvent is selected from ethanol, isopropyl acetate, a mixed solvent of dichloromethane and methanol, a mixed solvent of methyl ethyl ketone and methylcyclohexane, a mixed solvent of 1,4-dioxane and toluene, a mixed solvent of isopropyl alcohol and water, a mixed solvent of methyl isobutyl ketone and acetonitrile, and a mixed solvent of acetone and ethyl acetate; (4) Anhydrous Form C is dried at room temperature and converted into anhydrous Form A.

6. The method for preparing the anhydrate form C according to claim 2, comprising any one of the following methods: (1) suspending the compound of formula (1) in a solvent and stirring at 5-35° C. for 1-3 days to obtain a crystalline wet sample of Form B; drying Form B at 50-80° C. to convert it into anhydrous Form C; the solvent is selected from ethanol and a mixed solvent of ethyl acetate and isopropanol; (2) suspending the compound of formula (1) in a solvent, stirring at 4-8° C. for 3 days, and separating the solid to obtain anhydrous crystalline form C; the solvent is selected from a mixed solvent of ethyl acetate and isopropanol; (3) The compound of formula (1) is suspended in a solvent, stirred at room temperature for 14-18 days, and then the solid is separated to obtain anhydrous crystal form C; the solvent is selected from a mixed solvent of acetonitrile and water.

Citation Information

Patent Citations

  • Application of RNA helicase DHX33 inhibitor in preparation of medicine for treatment of leukemia

    CN113616644A

  • Polycyclic compound for inhibiting RNA helicase DHX33 and application thereof

    CN115536648A

  • Sulfate crystal form of amide compound, pharmaceutical composition and application

    CN115710257A

  • Hydrochloride crystal form of amide compound, pharmaceutical composition and application

    CN116003394A

  • Methanesulfonate crystal form of compound, pharmaceutical composition and application

    CN116120301A